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Available online 27 July 2014Abstract Fanconi anemia (FA) is an autosomal recessive disorder characterized by progressive bone marrow failure (BMF)
during childhood, aside from numerous congenital abnormalities. FA mouse models have been generated; however, they do not
fully mimic the hematopoietic phenotype. As there is mounting evidence that the hematopoietic impairment starts already in
utero, a human pluripotent stem cell model would constitute a more appropriate system to investigate the mechanisms
underlying BMF in FA and its developmental basis. Using zinc finger nuclease (ZFN) technology, we have created a knockout of
FANCA in human embryonic stem cells (hESC). We introduced a selection cassette into exon 2 thereby disrupting the FANCA
coding sequence and found that whereas mono-allelically targeted cells retain an unaltered proliferation potential, disruption
of the second allele causes a severe growth disadvantage. As a result, heterogeneous cultures arise due to the presence of cells
still carrying an unaffected FANCA allele, quickly outgrowing the knockout cells. When pure cultures of FANCA knockout hESC
are pursued either through selection or single cell cloning, this rapidly results in growth arrest and such cultures cannot be
maintained. These data highlight the importance of a functional FA pathway at the pluripotent stem cell stage.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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rho-associated proteine kinase; Puro cassette, Puromycin resistance
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comparative genomic hybridization; HA, homology arms; SB, Southern
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Fanconi anemia (FA) is an autosomal recessive disease
characterized by congenital abnormalities and progressive bone
marrow failure (BMF) in the first decades of life, which develops
into hematologic malignancies in 33% of cases (Kutler et al.,
2003; Auerbach, 2009). The high cancer predisposition and
hypersensitivity to cross-linking agents (Sasaki and Tonomura,
1973; Ishida and Buchwald, 1982; Auerbach et al., 1989), used
as a diagnostic criterion, reflect the genomic instability of these
patients and illustrate the link with DNA repair processes. FA
results from mutations in any of the 16 genes linked together
in the FA pathway (FANCA, FANCB, FANCC, FANCD1, FANCD2,n access article under the CC BY-NC-ND license
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FANCO, FANCP, FANCQ) (Garaycoechea and Patel, 2014). This
pathway is activated upon detection of DNA damage to help
resolve stalled replication forks at double strand breaks (DSB)
and promote faithful DNA repair through homologous recom-
bination (HR) (Kee and D'Andrea, 2010; Adamo et al., 2010;
Pace et al., 2010). When the FA pathway is disrupted, DSB are
no longer diverted away from the more error-prone non-
homologous end-joining (NHEJ) repair pathway in favor of HR,
which likely results in the acquisition of cytogenetic abnor-
malities (Adamo et al., 2010; Pace et al., 2010; Blanpain et
al., 2011).
It is well understood that cytogenetic abnormalities underlie
events such as leukemic transformation (Look, 1997). Insights
on how accumulation of DNA damage contributes to progres-
sive BMF, however, have only recently started to emerge
(Niedernhofer, 2008; Milyavsky et al., 2010; Zhang et al.,
2011; Blanpain et al., 2011). Ceccaldi et al. demonstrated that
BMF in FA is triggered by an exacerbated p53/p21 DNA damage
response that impairs hematopoietic stem and progenitor cells
(HSPC), leading to the progressive elimination of these cells in
FA patients (Ceccaldi et al., 2012). Furthermore, hypersensi-
tivity to cross-linking agents and thus the genomic instability
can be restored to wild type (WT) levels in somatic FA cells
when the NHEJ pathway is inhibited (Adamo et al., 2010; Pace
et al., 2010). Whether NHEJ inhibition in FA-deficient cells
would also restore the hematopoietic defects by reducing
genomic instability and concomitant accumulation of DNA
damage is unknown.
Although FA knockout mouse models have been established,
they do not display spontaneous BMF and therefore do not fully
mimic the hematopoietic condition seen in FA patients (Parmar
et al., 2009). For this reason, a human disease model is more
informative when investigating the mechanisms underlying the
progressive BMF. Moreover it has been suggested that the
hematopoietic defect in FA already starts in utero with a
reduced HSPC pool during prenatal life, which is further
challenged by additional age-related cellular stress and DNA
damage resulting in HSPC exhaustion and BMF during childhood
(Tulpule et al., 2010; Ceccaldi et al., 2012; Kamimae-Lanning et
al., 2013). In this context, a human pluripotent stem cell model
for FA would create an opportunity to interrogate the
mechanism(s) underlying the decreased HSPC pool during
development, and determine the role of aberrant NHEJ usage
on hematopoiesis during the earliest stages of hematopoietic
ontogeny, captured in the process of hematopoietic differen-
tiation from pluripotent cells.
In 2009, Raya et al. found that somatic cells from FA patients
could only be reprogrammed after correction of the genetic
defect, suggesting an important role for the FA pathway in
establishing pluripotency (Raya et al., 2009). However, Tulpule
et al. subsequently created the first human-specific pluripotent
FA stem cell model in hESC through knockdown (KD) of FA
proteins using a lentiviral RNA interference (RNAi) approach
(Tulpule et al., 2010). Recently it has been demonstrated that
the reprogramming process itself triggers DNA damage and
that efficient reprogramming requires key HR genes, including
Brca1, Brca2 (Fancd1) and Rad51 (Gonzalez et al., 2013;
Navarro et al., 2014). Given the close interplay of the FA
and HR DNA repair pathways, it might not be surprising that
difficulties are seen upon reprogramming FA-deficient
cells. Nevertheless, several groups recently succeeded inreprogramming uncorrected FA patient cells, albeit with
low efficiency (Muller et al., 2012; Yung et al., 2013; Liu et
al., 2014). In addition, many of the established FA human
induced pluripotent stem cell (hiPSC) lines could not be
maintained in culture for more than a few passages (Yung et
al., 2013). Together, these reports on FA hiPSC suggest an
important role for the FA pathway not only in the establishment
of pluripotency but also in the maintenance of pluripotent stem
cells.
The aim of our study was to establish a human pluripotent
disease model for FA through the creation of a FANCA
knockout in hESC that would allow addressing the influence
of loss of FANCA on hematopoietic development without
interference of possible reprogramming-mediated mutations
or the mutational load that somatic FA cells have collected
during their life span, likely present in FA hiPSC. We
demonstrate that FANCA knockout (FANCA−/−) hESC, in
contrast to the previously established FA KD hESC model,
display a severe growth disadvantage at the pluripotent stage,
consistent with the notion that the FA pathway is vital for
pluripotent stem cell proliferation.
Material and methods
hESC culture and maintenance
hESC line H9 (WA09) was purchased from WiCell Research
Institute. H9 cells and all ZFN-targeted clones derived
from it were expanded on inactivated mouse embryonic
fibroblast (MEF) feeder layers in hESC medium (DMEM/F12
(Invitrogen) supplemented with 20% KnockOut Serum
Replacement (Invitrogen), 1% non-essential amino acids
(Invitrogen), 1 mM L-glutamine (Sigma-Aldrich), 0.1 mM
β-mercaptoethanol (Sigma-Aldrich) and 4 ng/ml bFGF
(Peprotech)). Feeder-free (FF) cultures for DNA sampling
purposes were established by passaging the hESC onto
Matrigel (Becton Dickinson)-coated plates in mTeSR I medium
(Stemcell Technologies). Single cell dissociation to establish
clonal cultures was performed with Trypsin 0.05% (Invitrogen)
for MEF cultures or Accutase (Sigma) for FF cultures and cells
were plated in medium containing 10 mM ROCK inhibitor
(Sigma-Aldrich). Following the second targeting, cells were
cultured at 37 °C in 5% CO2 and 5% O2.
FANCA targeting
A specific ZFN set for FANCA (Sigma-Aldrich) was generated
targeting the first nucleotides of exon 2 (validation results in
Fig. S1). A targeting vector carrying a selection cassette and
homology arms flanking the double strand break was created
so that its site-specific incorporation would disrupt the
FANCA coding sequence (Fig. 1A). The different components
for the FANCA targeting vector were cloned into the pCR2.1
plasmid (Life Technologies). The plasmids used for the first
(Fig. S2) and second (Fig. S3) rounds of targeting carry
Puromycin (Puro) and Hygromycin (Hygro) resistance cassettes
respectively. Two million hESC were nucleofected with the
targeting vector (11.5 μg for Puro and 12 μg for Hygro
targeting) and 5 μl of ZFN mRNA using hESC Nucleofector
solution 2 (Lonza), program A13 following the manufacturer's
instructions. Cells were plated on inactivated DR4 MEF
Figure 1 Schematic overview of ZFN-mediated FANCA targeting and demonstration of targeted integration in Puromycin-resistant
clones. A) The FANCA locus and the expectedmodifications after each round of targeting are shown. Primers used to amplify thewild type
allele (WT1 + WT2), the Puromycin (P1 + P2) and Hygromycin (H1 + H2) junctions by PCR are indicated. Thick black areas flanking the
double strand break (DSB) depict homology arms (HA). Probe used for Southern blot (SB probe) is shown with a gray part annealing to the
WT FANCA locus and awhite part annealing to the EF1a promoter. Dashed vertical lines indicate DraI restriction sites for SB. B) Puromycin
junction assay (primers P1 + P2) for a representative set of Puromycin-resistant clones with a positive control for the junction (P+) and
untargeted hESC (H9) as a negative control. C) Southern blot (SB) results for representative set of Puromycin-resistant clones after DraI
digest of genomic DNA. D) SB results after DraI digest shown for (left panel) clone 1 after initial selection but before Puromycin reselection
(P1), (middle panel) clone 1 immediately after Puromycin reselection (P1+PURO) and its unselected parallel culture at that time (P1−PURO),
(right panel) clone 1 some passages after Puromycin reselection (P1NPURO). The probe anneals to both the transgenic EF1a promoter (TG)
and the endogenous human EF1a promoter (hEF1a). hESC (H9)were taken as an untargeted reference for thewild type (WT) allele. Clones
with random integration events are marked with *.
242 K. Vanuytsel et al.(GlobalStem) in media containing 10 mM ROCK inhibitor
(Sigma-Aldrich). The Puro targeted hESC were selected with
300 ng/ml Puromycin (Sigma-Aldrich) and resistant colonies
were individually picked and expanded after 7–13 days.
After Hygro targeting, selection with up to 30 μg/ml of
Hygromycin (Sigma-Aldrich) was performed. Surviving colonies
were individually picked and expanded after 10 days. In the
reselection process up to 500 ng/ml of Puromycin was used for
Puro targeted clones and concentrations up to 50 μg/ml of
Hygromycin in the case of Hygromycin reselection.PCR genotyping
Genotyping PCRs were performed according to standard
procedures using primers listed in Table S4. A schematic
representation of the primer pairs can be found in Fig. 1A.
For the Puromycin and Hygromycin junction assays a forward
primer annealing to the selection cassette and a reverse
primer in the FANCA locus outside the homology arms (HA)
were combined. The correct amplification of the junctions
was confirmed through sequencing both in controls and
243FANCA knockout in human embryonic stem cells causes a severe growth disadvantagesamples. Positive controls used for the junction assays are
listed in Table S5. Primers flanking the double strand break
(DSB) were used for the WT allele amplification assay and
correct amplification was confirmed through sequencing. To
assess random integration by PCR two sets of primers were
designed along the backbone of the plasmid used during
ZFN-mediated targeting.Proliferation kinetics
The growth delay of clones cultured on MEF and on Matrigel
(FF) was visualized by plotting the subsequent passages
(y-axis) against a cumulative growth delay factor (x-axis),
which was calculated as follows: time to reach confluence
(time between subsequent passages in days) divided by
expansion factor: “time to confluence/expansion factor”.
This means that the longer it takes for a culture to become
confluent (increase in numerator) or the less it can be
expanded (decrease in denominator), the bigger the increase
on the x-axis. This will result in a flatter slope for slow growing
cultures and a steeper slope for fast growing cultures. The
values used to calculate the cumulative growth delay for
each cell line can be found in Table S6 (MEF) and Table S7
(FF).Southern blot analysis
Genomic DNA was isolated using the QiaAmp DNA mini kit
(Qiagen). Southern blots were performed using the DIG High
Prime DNA Labeling and Detection starter kit II (Roche)
according to the manufacturer's instructions. The primer set
used for the generation of the Southern blot probe can be
found in Table S4. A schematic representation of the probe
and the fragment sizes after DraI (Fermentas) digestion can
be found in Fig. 1A.aCGH
Genomic DNA was isolated using the QiaAmp DNA mini kit
(Qiagen). Samples were hybridized against commercially
available female control DNA (Kreatech) and subjected to a
whole genome analysis using 180 k Cytosure ISCA v2 arrays
(Oxford Gene Technologies). Array data were extracted
using Feature Extraction software v10.7 and visualized using
CytoSure Interpret Software V4.5.3. Copy number altered
regions were detected using statistics provided by the CytoSure
Interpret Software V4.5.3, considering a minimum number of
five consecutive probes.Western blot analysis
Western blot analysis was performed using a rabbit poly-
clonal antibody for FANCA (1:2000; Abcam) and a mouse
monoclonal antibody for GAPDH (1:5000; Santa Cruz
Biotechnology) followed by horseradish peroxidase-conjugated
swine anti-rabbit secondary antibody (1:3000; Dako) and goat
anti-mouse secondary antibody (1:3000; Dako) respectively.QuantiGene® FlowRNA assay
Probes against Puromycin N-acetyl-transferase and hygromycin
B phosphotransferase mRNA transcripts were designed by
Affymetrix. The QuantiGene® FlowRNA assay (Affymetrix) was
conducted according to the manufacturer's instructions. Data
was analyzed by FlowJo software.Results
Growth advantage for FANCA+/− hESC over
FANCA−/− hESC
To create a human pluripotent stem cell model for FA, we
aimed at knocking out FANCA in hESC through insertion of a
Puromycin resistance (Puro) cassette in exon 2, thereby
disrupting the FANCA coding sequence. As FA is a recessive
disease, bi-allelic targeting is required to establish the
appropriate model. After nucleofection of hESC (H9) with a
FANCA-specific ZFN pair and a donor plasmid harboring a
Puro cassette flanked by homology arms (HA) (Fig. 1A),
recombinant clones were selected with 300 ng/ml Puromycin.
Resistant colonies were picked after 7–13 days of selection
and site-specific integration of the Puro cassette could be
demonstrated in 37 out of 50 clones through amplification of
the cassette junction by PCR (Fig. 1B). Southern blot (SB) data
confirmed the targeted integration of the Puro cassette but as
the WT allele could still be detected in all clones, no bi-allelic
targeting events could be identified (Fig. 1C). For one clone
(clone P1), SB suggested a higher abundance of transgenic
than WT alleles (Fig. 1C). As hESC were split as clumps rather
than through single cell dissociation, we hypothesized that
this clone might represent a mixture of mono-allelically
(FANCA+/−) and bi-allelically (FANCA−/−) targeted cells both
withstanding the applied selection pressure. Disappearance of
the band corresponding to the WT allele upon reselection with
500 ng/ml Puromycin confirmed this hypothesis (Fig. 1D). This
coincidedwith the observation that some colonies in the culture
disappeared upon reselection whereas others seemed not to
be affected by this higher concentration. However, when
the same clone was assessed by SB a few passages after
Puromycin reselection, the WT allele was again detected
(Fig. 1D), suggesting a selective growth advantage of FANCA+/−
cells, which can escape or withstand selection pressure, over
FANCA−/− cells.
FANCA −/− hESC display a severe growth disadvantage
resulting in growth arrest
As we were unable to maintain bi-allelically targeted hESC
as a pure population of FANCA−/− cells, we adopted an
alternative targeting approach wherein we nucleofected
mono-allelically targeted hESC (FANCA+/−) with a second
selection cassette (Fig. 1A). First, an additional round of
Puromycin selection was conducted on a clone previously
confirmed to carry a unique insertion of the Puro cassette
in FANCA (clone P21) to eliminate possible remnants of
untargeted cells. Next, a Hygromycin resistance (Hygro)
cassette was inserted into the untargeted allele via a second
round of ZFN-mediated HR. We identified several clones
244 K. Vanuytsel et al.carrying both a Hygro and a Puro cassette in the FANCA locus
as judged by the amplification of the respective junctions by
PCR (Figs. 2A,B). Further confirmation of bi-allelic targeting
was seen in the inability to amplify the WT allele in some of
these (Fig. 2C). Clones fitting all three criteria of bi-allelic
targeting (clones PH4, PH16 and PH18) were chosen for
further expansion, as these were considered FANCA−/− hESC.
Though undetectable in the first passage after ZFN
targeting, the WT FANCA allele could again be amplified in
nearly all clones the next passage both in cultures on
inactivated mouse embryonic fibroblasts (MEF) as well as in
feeder-free (FF) cultures (Figs. 2D, E). The different amplicons
were sequenced to verify that they indeed represented the
expected cassette junctions or WT allele. To further purify
FANCA−/− cells, Hygromycin selection was reinitiated. The
three bi-allellically targeted clones cultured on MEF showed a
profound growth delay and underwent growth arrest one
passage (19–22 days) after reinitiation of Hygromycin selection
(Fig. 3A). Following splitting, only a few colonies attached. The
colonies that attached displayed the characteristic hESC
appearance without any signs of differentiation but showed
only a minimal increase in size and after some time remained as
such without any visible growth. Clones maintained feeder-free
however, though clearly affected, did not all display the same
rate of growth arrest as on MEF (Fig. 3B). The most severe
growth delaywas seen in clone PH16where, in contrast to other
clones, the WT allele did not reappear immediately the next
passage. Whereas culture of untargeted hESC on Matrigel
requires colonies to be split about every 5 days, clone PH16
did not reach confluency even after 14 days in the absence of
selection. Clone PH18 on the other hand, clearly affected by
Hygromycin selection as the time between subsequent passages
increased to roughly two-fold the regular 5-day interval, could
be kept in culture for an extended number of passages. DNA
taken at subsequent passages under Hygromycin reselection
continuously showed amplification of the WT allele in additionFigure 2 PCR genotyping for Hygromycin-resistant clones. A–E) PC
resistant clones. A) Hygromycin junction assay with a positive control fo
B) Puromycin junction assaywith a positive control for the junction (P+) a
amplification assay at the first passage after picking Hygromycin-resist
conditions (E). H9 are included as a positive control for the WT locus.to both cassette junctions (Figs. 3C,D,E). The presence of WT
FANCA in spite of clear demonstration of bi-allelic targeting in
PH18 was further substantiated by Western blot data demon-
strating FANCA protein expression (Fig. 3F). Attempts to
establish clonal cultures from this clone and others through
single cell dissociation were not successful as few cells grew out
to become colonies and these quickly displayed growth arrest.
Demonstration of bi-allelic targeting at the single
cell level
To unequivocally demonstrate that FANCA knockout cells
are present within this culture initially confirmed to be
bi-allelically targeted based on the amplification of both
Puro and Hygro cassette junctions and the absence of the WT
allele, we made use of the QuantiGene® FlowRNA assay.
Using probes against Puromycin N-acetyl-transferase and
Hygromycin B phosphotransferase mRNA transcripts we ana-
lyzedwhether these selection cassette transcripts were present
together at the single cell level. The FlowRNA assay clearly
demonstrates that clone PH18 harbors a population of cells
positive for both the Puro and Hygro cassettes (Fig. 4A). As we
also verified the absence of random integrations in this clone
both by SB and PCR (Figs. 4B, C), we can safely conclude that
this population represents a FANCA knockout hESC population
with a Puro cassette disrupting one allele of FANCA and a Hygro
cassette disrupting the other.
Heterogeneity in FANCA−/− cultures
As FA is associated with genomic instability and genetic
rearrangements are recurrently found in iPSC generated
from FA-deficient cells (Muller et al., 2012; Yung et al., 2013),
we investigated whether rearrangements in the genome of
these bi-allelically targeted clones could possibly explain theR genotyping results during the first two passages of Hygromycin-
r the junction (H+) and untargeted hESC (H9) as a negative control.
nd untargeted hESC (H9) as a negative control. C–E)Wild type allele
ant colonies (C) or after one additional passage on MEF (D) or in FF
Figure 3 Bi-allelically targeted clones show a severe growth disadvantage and a persistent presence of WT FANCA in those cultures
that can be maintained in culture. A) Proliferation kinetics of cultures on MEF. Values on the x-axis are representative for the growth
delay a certain cell line displays. These values are calculated as time to reach confluence (time between subsequent passages in days)
divided by expansion factor: “time to confluence/expansion factor”. This means that the longer it takes for a culture to be confluent
(increase in numerator) or the less it can be expanded (increase in denominator), the bigger the increase on the x-axis. This will result
in a flatter slope for slow growing cultures and a steeper slope for fast growing cultures. The arrow indicates the start of Hygromycin
reselection. Untargeted H9 (H9) are included as a reference (unselected) and a mono-allelically Hygro targeted cell line (PH8(mono))
cultured in parallel under the same Hygromycin selection regimen is included as a control. * indicates when maintenance of the
culture became impossible due to growth arrest. # represents the point at which a confluent culture was frozen. B) Proliferation
kinetics of FF cultures. Passages under Hygromycin reselection are labeled as H1–H6 on the right axis. The arrow indicates the start of
Hygromycin reselection. Untargeted H9 (H9) are included as a reference (unselected) and a mono-allelically Hygro targeted cell line
(PH14(mono)) cultured in parallel under the same Hygromycin selection regimen is included as a control. * indicates when maintenance of
the culture became impossible due to growth arrest. # represents the point at which a confluent culture was frozen. ° indicates the point at
which cultures were discontinued due to persistent heterogeneity or after the confirmation of loss of the FANCA−/− cells. C) Puromycin
junction assaywith a positive control for the junction (P+) and untargeted HepG2 andH9 as negative controls. D) Hygromycin junction assay
with a positive control for the junction (H+) and untargeted HepG2 and H9 as negative controls. E) Wild type allele amplification assay with
untargeted HepG2 and H9 included as positive controls for theWT locus. F)Western blot showing FANCA expression in Hygromycin-resistant
clones with untargeted H9 as a reference.
245FANCA knockout in human embryonic stem cells causes a severe growth disadvantagegenotyping results, where three different versions of the
FANCA locus could be identified. An array comparative
genomic hybridization (aCGH) screenwas performed on clones
PH4 and PH18 (Fig. 5), which did not reveal significant copy
number variations compared to the untargeted hESC line or
clone P21 used for the second round of targeting with a Hygro
cassette. For clone PH18 however, a duplication of 6.6 Mb onthe short arm of chromosome 5 (5p14.1p13.2(28,340,612–
35,004,191) × 3) was detected shortly after targeting that was
not present in clone P21 from which the clone was derived.
The duplication could no longer be detected in a subsequent
sample of clone PH18 following a few passages. This suggests
that this duplication arose in a subpopulation of cells that then
disappeared from the culture over the next passages.
Figure 4 Demonstration of bi-allelic targeting at the single cell level. A) Flow RNA plot showing Puromycin N-acetyl-transferase
(Puro probe) and Hygromycin B phosphotransferase (Hygro probe) expression for clone PH18 (red) compared to untargeted H9 (blue).
B) Southern blot after DraI digest for clone PH18 after 2 (H2) and 5 (H5) passages under Hygromycin reselection demonstrating absence
of random integrations. C) PCR results demonstrating absence of random integrations. Untargeted H9 were included as negative
control. Positive controls are HEK293 harboring randomly integrated pieces of the plasmid used for targeting (+) and the targeting
plasmid itself (plasmid). Upper and lower panels represent primers spanning the backbones 3′ and 5′ from the selection cassette
respectively.
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of cells were found in the behavior of clone PH4. PCR data
showed that for clone PH4 the Puro junction could no longer
be amplified at passage 3 during Hygromycin reselection (H3)
whereas the passage before (H2) (Fig. 3C) it was still
present. This was confirmed by the simultaneous loss of
Puromycin resistance; hence again creating a mono-allelically
targeted cell population. This is consistentwith the hypothesis
that the culture remains mixed, and that the FANCA−/−
subpopulation disappears due to its inherent growth disad-
vantagewhile others, not bi-allelically targeted, take over the
culture. Further corroborating this hypothesis is the fact that
the H2 culture required 14 days to reach sufficient confluence
to be split into H3 (Fig. 3B). From H3 onwards, the growth rate
of the now mono-allelically targeted cells was restored to
levels similar to those of untargeted H9.Discussion
Fanconi anemia is an intriguing yet devastating condition at
the intersection of DNA repair and hematopoietic dysfunc-
tion. Whereas the functions of FA proteins in DNA repair are
well documented (Moldovan and D'Andrea, 2009; de Winter
and Joenje, 2009), the mechanism underlying the character-
istic BMF is less well understood as many model systems,
including FA knockout mice, fail to recapitulate the hemato-
poietic phenotype in all its aspects (Parmar et al., 2009).
Recently however, clues on how these two features are linked
came from the demonstration that an exacerbated p53/p21
DNA damage response impairs HSPC causing progressive
elimination of these cells in FA patients, ultimately resulting
in BMF (Ceccaldi et al., 2012). Compared with normal fetal
liver samples, p21 levels in the liver from FA fetuses were
significantly higher, consistent with the onset of FA-induced
loss of HSPC during prenatal life. To identify the earliest
effects of FA deficiency on hematopoietic development, we
aimed at creating a human pluripotent FA stem cell model.
We generated a FANCA knockout in hESC via ZFN-mediated
HR, disrupting both alleles of FANCA. Such FANCA knockouthESC, however, displayed a severe growth disadvantage,
which paves the way for non-FA-deficient cells, be it
mono-allelically targeted or untargeted cells, to take over
the culture as they have a growth advantage over the
FA-deficient cells. When FANCA−/− hESC were purified from
these contaminating cells, either through selection or single
cell cloning, they rapidly underwent growth arrest and such
cultures could not bemaintained, making them not suitable as
a FA disease model.
Interfering with DNA repair at the pluripotent stage, tightly
regulated not to propagatemutations to its progeny (Fortini et
al., 2013; Rocha et al., 2013), is not without risks. However,
no problems in the maintenance of pluripotent cells were
reported after knocking down FA proteins in hESC (Tulpule et
al., 2010). Loss of p53 and ATM in hESC, to model two major
genetic instability syndromes, also did not affect hESC
proliferation (Song et al., 2010). Nevertheless, we here
demonstrate that whereas mono-allelically targeted cells have
unaltered proliferation potential compared to untargeted hESC,
disruption of the second FANCA allele causes a severe growth
disadvantage.
Initially it was postulated that a functional FA pathway is a
prerequisite for cells to be reprogrammed to the pluripotent
stage as reprogramming could only be achieved in FA patient
cells after correction of the FA defect (Raya et al., 2009). More
recently however, several groups demonstrated that FA cells
are resistant but not refractory to reprogramming as they
succeeded in generating FA iPSC, albeit at a greatly reduced
efficiency (Muller et al., 2012; Yung et al., 2013; Navarro et
al., 2014; Liu et al., 2014). Although Yung et al. succeeded in
reprogramming FA patient cells under normoxic conditions,
Muller et al. described a disease-associated advantage for
reprogramming FA cells under hypoxia and therefore used
hypoxic conditions to generate FA hiPSC (Muller et al., 2012;
Yung et al., 2013). In contrast to these reports and in agreement
with an exacerbated p53 stress response in FA cells (Ceccaldi et
al., 2012) and the rate-limiting effect of p53 on reprogramming
(Marion et al., 2009; Hong et al., 2009; Utikal et al., 2009), Liu
et al. could only generate FA hiPSC when p53 shRNA was added
to the reprogramming cocktail (Liu et al., 2014). When p53
Figure 5 aCGH data showing a duplication of 6.6 Mb at the short arm of chromosome 5 in clone PH18 shortly after targeting. Clones
PH4 and PH18 were analyzed by aCGH shortly after targeting and following 5 passages under Hygromycin reselection (H5). Untargeted
H9 cells and clone P21 from which clones PH4 and PH18 are derived were included in the screen as references. Log2 ratios are
depicted on the vertical axis.
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overcome despite the presence of epigenetic remodeler sodium
butyrate and hypoxic conditions. The integration-free FA hiPSC
generated in this study displayed slower kinetics as they
appeared only after 40 (instead of 22) days of reprogramming.
Moreover, a threefold reduction in the amount of colonies
present after seeding similar numbers of cells was observed for
FA hiPSC compared to control hiPSC (Liu et al., 2014). Besides
this decrease in clonogenicity described by Liu et al., also the
proliferation and/or maintenance of previously generated FA
hiPSC lines seemed to be compromised. Whereas Muller et al.
mentioned slightly delayed growth kinetics in FA hiPSC, Yung et
al. reported that most of the FA hiPSC lines established in their
study could not be maintained in culture for more than a few
passages (Muller et al., 2012; Yung et al., 2013). The only two
lines that could be maintained had a very abnormal karyotype,
which leaves room to speculate that genetic events possibly
compensating for the absence of the FA pathway enabled
successful reprogramming andmaintenance (Yung et al., 2013).
This would be consistent with the observation that corrected
FA iPSC fail to silence the transgenic FANCA copy after
reprogramming, suggesting a selective pressure for continued
correction of the FA pathway and that knockdown of the FANCAtransgene resulted in loss of hiPSC proliferation (Raya et al.,
2009; Muller et al., 2012). Combined with these data, our
findings convincingly support the relevance of a functional FA
pathway for the maintenance of pluripotent stem cells.
While others and we find that maintenance of pluripotent
stem cells is compromised in case of a defective FA pathway,
total absence of FANCA protein in humans does not reduce
embryonic viability (Castella et al., 2011). Most likely this
discrepancy can be contributed to the fact that hESC and
hiPSC are the in vitro equivalents of pluripotent cells found
in the blastocyst, artificially maintained in the undifferen-
tiated state through tailor-made culture conditions that
continuously stimulate the cells to divide symmetrically.
These in vitro stimuli expose the cells to high levels of
replicative stress that might not be present in vivo, or only
for a short period of time. In addition hESC and hiPSC are
inevitably exposed to oxidative stress during culture and when
handling the cells. Considering the sensitivity of FA-deficient
cells to oxidative and replicative stress (Joenje et al., 1981;
Schindler and Hoehn, 1988; Ceccaldi et al., 2012), these
elevated levels in culture in vitro compared to in vivo likely
account for an accumulation of DNA damage at a stage tightly
controlled not to propagate mutations to the progeny. This
248 K. Vanuytsel et al.might well be the underlying cause of the accelerated
replicative crisis observed in FANCA knockout hESC and FA
hiPSC.
In this study we were also confronted with heterogeneous
cultures of mono-allelically and bi-allelically targeted cells
both withstanding the applied selection pressure. Similar
mixtures have been reported after ZFN targeting (Yao et al.,
2012) and are a direct consequence of the fact that hESC are
generally passaged as clumps rather than through single cell
dissociation. Immediately after targeting, the cells are plated
as single cells, which then grow into resistant colonies during
the selection process. When selection is complete, judged by
the elimination of untargeted cells in a control well exposed to
the same concentration of the antibiotic, resistant colonies
are manually cut in smaller pieces to establish a subculture.
The resulting culture is not necessarily clonal in nature, as we
cannot exclude the presence of different cell clones in one
resistant colony. In fact, data obtained shortly after targeting
suggests the co-existence of some incompletely targeted cells
amongst the bulk of bi-allelically targeted hESC as the WT
band that could not be detected by PCR in the first passage
after targeting could again be amplified one passage later in
most clones. This demonstrates that non-FA-deficient cells,
even when representing a negligible percentage of the total
population, quickly out-proliferate FANCA knockout cells due
to the inherent growth disadvantage of the latter. This
observation is akin to somatic mosaicism which confers a
selective growth advantage over FA-deficient cells onto their
gene corrected counterparts (Waisfisz et al., 1999; Gregory et
al., 2001; Gross et al., 2002). Moreover our data suggest that
even though antibiotic concentrations were used that were
carefully titrated to result in complete elimination of unmod-
ified hESC, still some untargeted cells managed to persist and
give rise to heterogeneous cultures. Attempts to establish
clonal cultures through single cell dissociation to circumvent
this issue were not successful as the few colonies that grew out
rapidly displayed growth arrest.
Given the severely compromised proliferation upon disrup-
tion of the second FANCA allele, we have considered combining
the knockout strategy with an inducible overexpression of
FANCA, whichwould allow bi-allelic targeting in the presence of
a functional FA pathway. Even though this could facilitate the
initial characterization of the bi-allelic targeting, at the point
where we would induce the knockout by removing the
transgenic FANCA expression, similar complications as discussed
above would most likely arise. Irrespective of the method
(Cre–LoxP, FRT–Flipase, doxycycline inducible systems), it
remains challenging to completely eliminate the expression of
the transgenic FANCA in all cells of the culture. As our data
show that even a negligible amount of non-FA-deficient cells
can quickly take over resulting in a heterogeneous culture and
that rapid growth arrest occurs when we try to circumvent
such heterogeneity issues by generating clonal knockout cell
lines, we believe that considerable technical challenges will
prevent us from obtaining a pure FANCA−/− population for
further functional testing, even with a conditional approach.Conclusion
The inherent growth defect of FANCA knockout hESC reported
in this study hampers the establishment of a humanpluripotent FA disease model and therefore our question
whether disabling error-prone DNA repair in a FA context
would restore hematopoiesis, as it does for the genomic
instability in somatic FA cells, remains unanswered. The
creation of a FANCA knockout in hESC however did allow us
to address the consequences of a complete loss of FANCA at
the pluripotent stage in an unbiased way as the cells
established in this study did not carry any mutational load
associated with reprogramming in a DNA repair-deficient
context. We show that disabling the FA pathway in hESC by
disrupting both copies of FANCA (FANCA−/−) leads to a severe
growth disadvantage, ultimately resulting in growth arrest. As
such, FANCA knockout hESC surface additional problems
compared to a FA KD hESC model, possibly reflecting a
difference between the complete absence of a functional FA
pathway and presence of some residual FA proteins, albeit at
very low amounts. It cannot be excluded however that other
variables such as the culture system and in vitro stress levels
are also in part responsible for the extent to which a growth
deficit becomes apparent as a recently generated FANCA
knockout hESC model displayed milder growth deficits at the
pluripotent stage than what is reported here (Liu et al., 2014).
Nevertheless, the demonstration that proliferation is compro-
mised in FA-deficient pluripotent stem cells is a consistent
observation in agreement with recent reports on FA hiPSC and
emphasizes the importance of a functional FA pathway at the
pluripotent stem cell stage.
Acknowledgments
The authors acknowledge Rob Van Rossom and Thomas
Vanwelden for technical assistance.
KV and QC were funded by IWT (SB-091228 and SB-093228;
SB-71255 and SB-73255); LO by Gobierno de Aragon (FMI048/
08), Instituto Aragonés de Ciencias de la Salud (BPAMER3/08/
04) and IWT (OZM-090838). SK was funded by FWO (PDO/10
and KAN2014). KU Leuven (SCIL PF/10/019, OT/09/053,
EJJ-C6086-2012-194, EJJ-C2584-G.0851.11), BELSPO-IUAP-
DEVREPAIR (EJJ-C4851-P7/07-P), FWO G.0452.06 and
FWO Odysseus award (G.0667.07) were granted to CMV.
Authorship contributions
KV designed and performed the research, analyzed and
interpreted the results and wrote the manuscript. QC designed
the research and interpreted results. NN and SS performed the
research and analyzed the results. SK analyzed the data,
interpreted the results and edited themanuscript. JRV designed
the aCGH experiments, interpreted the results and edited the
manuscript. LO and CMV designed the research, interpreted the
results and edited the manuscript.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.scr.2014.07.005.
References
Adamo, A.,Collis, S.J.,Adelman, C.A.,Silva, N.,Horejsi, Z.,Ward, J.D.,
Martinez-Perez, E., Boulton, S.J., La Volpe, A., 2010. Preventing
nonhomologous end joining suppresses DNA repair defects of Fanconi
249FANCA knockout in human embryonic stem cells causes a severe growth disadvantageanemia. Mol. Cell 39 (1), 25–35. http://dx.doi.org/10.1016/j.
molcel.2010.06.026 (S1097-2765(10)00493-4 [pii]).
Auerbach, A.D., 2009. Fanconi anemia and its diagnosis. Mutat. Res.
668 (1–2), 4–10. http://dx.doi.org/10.1016/j.mrfmmm.2009.
01.013 (S0027-5107(09)00053-0 [pii]).
Auerbach, A.D., Rogatko, A., Schroeder-Kurth, T.M., 1989. Interna-
tional Fanconi Anemia Registry: relation of clinical symptoms to
diepoxybutane sensitivity. Blood 73 (2), 391–396.
Blanpain, C., Mohrin, M., Sotiropoulou, P.A., Passegue, E., 2011.
DNA-damage response in tissue-specific and cancer stem cells.
Cell Stem Cell 8 (1), 16–29. http://dx.doi.org/10.1016/j.stem.
2010.12.012 (S1934-5909(10)00707-1 [pii]).
Castella, M.,Pujol, R.,Callen, E.,Trujillo, J.P.,Casado, J.A.,Gille, H.,
Lach, F.P., Auerbach, A.D., Schindler, D., Benitez, J., Porto, B.,
Ferro, T.,Munoz, A.,Sevilla, J.,Madero, L.,Cela, E.,Belendez, C.,
de Heredia, C.D.,Olive, T.,de Toledo, J.S.,Badell, I.,Torrent, M.,
Estella, J., Dasi, A., Rodriguez-Villa, A., Gomez, P., Barbot, J.,
Tapia, M.,Molines, A.,Figuera, A.,Bueren, J.A.,Surralles, J., 2011.
Origin, functional role, and clinical impact of Fanconi anemia
FANCA mutations. Blood 117 (14), 3759–3769. http://dx.doi.org/
10.1182/blood-2010-08-299917 (blood-2010-08-299917 [pii]).
Ceccaldi, R.,Parmar, K.,Mouly, E.,Delord, M.,Kim, J.M.,Regairaz, M.,
Pla, M.,Vasquez, N.,Zhang, Q.S.,Pondarre, C.,Peffault de Latour,
R., Gluckman, E., Cavazzana-Calvo, M., Leblanc, T., Larghero, J.,
Grompe, M., Socie, G., D'Andrea, A.D., Soulier, J., 2012. Bone
marrow failure in Fanconi anemia is triggered by an exacerbated
p53/p21 DNA damage response that impairs hematopoietic stem
and progenitor cells. Cell Stem Cell 11 (1), 36–49. http://dx.doi.
org/10.1016/j.stem.2012.05.013 (S1934-5909(12)00247-0 [pii]).
de Winter, J.P., Joenje, H., 2009. The genetic and molecular basis
of Fanconi anemia. Mutat. Res. 668 (1–2), 11–19. http://dx.doi.
org/10.1016/j.mrfmmm.2008.11.004 (S0027-5107(08)00282-0
[pii]).
Fortini, P.,Ferretti, C.,Dogliotti, E., 2013. The response to DNA damage
during differentiation: pathways and consequences. Mutat. Res.
743–744, 160–168. http://dx.doi.org/10.1016/j.mrfmmm.2013.03.
004 (S0027-5107(13)00022-5 [pii]).
Garaycoechea, J.I., Patel, K.J., 2014. Why does the bone marrow
fail in Fanconi anemia? Blood 123 (1), 26–34. http://dx.doi.org/
10.1182/blood-2013-09-427740 (blood-2013-09-427740 [pii]).
Gonzalez, F., Georgieva, D., Vanoli, F., Shi, Z.D., Stadtfeld, M.,
Ludwig, T., Jasin, M., Huangfu, D., 2013. Homologous recombi-
nation DNA repair genes play a critical role in reprogramming to
a pluripotent state. Cell Rep. 3 (3), 651–660. http://dx.doi.org/
10.1016/j.celrep.2013.02.005 (S2211-1247(13)00064-8 [pii]).
Gregory Jr., J.J.,Wagner, J.E.,Verlander, P.C.,Levran, O.,Batish, S.
D., Eide, C.R., Steffenhagen, A.,Hirsch, B., Auerbach, A.D., 2001.
Somatic mosaicism in Fanconi anemia: evidence of genotypic
reversion in lymphohematopoietic stem cells. Proc. Natl. Acad.
Sci. U. S. A. 98 (5), 2532–2537. http://dx.doi.org/10.1073/pnas.
051609898 (051609898 [pii]).
Gross, M.,Hanenberg, H.,Lobitz, S.,Friedl, R.,Herterich, S.,Dietrich,
R.,Gruhn, B.,Schindler, D.,Hoehn, H., 2002. Reverse mosaicism in
Fanconi anemia: natural gene therapy via molecular self-correction.
Cytogenet. Genome Res. 98 (2–3), 126–135 (doi: 6980569805 [pii]).
Hong, H., Takahashi, K., Ichisaka, T., Aoi, T., Kanagawa, O.,
Nakagawa, M., Okita, K., Yamanaka, S., 2009. Suppression of
induced pluripotent stem cell generation by the p53–p21 pathway.
Nature 460 (7259), 1132–1135. http://dx.doi.org/10.1038/
nature08235 (nature08235 [pii]).
Ishida, R., Buchwald, M., 1982. Susceptibility of Fanconi's anemia
lymphoblasts to DNA-cross-linking and alkylating agents. Cancer
Res. 42 (10), 4000–4006.
Joenje, H.,Arwert, F.,Eriksson, A.W.,de Koning, H.,Oostra, A.B., 1981.
Oxygen-dependence of chromosomal aberrations in Fanconi's anae-
mia. Nature 290 (5802), 142–143.
Kamimae-Lanning, A.N., Goloviznina, N.A., Kurre, P., 2013. Fetal
origins of hematopoietic failure in a murine model of Fanconianemia. Blood 121 (11), 2008–2012. http://dx.doi.org/10.1182/
blood-2012-06-439679 (blood-2012-06-439679 [pii]).
Kee, Y.,D'Andrea, A.D., 2010. Expanded roles of the Fanconi anemia
pathway in preserving genomic stability. Genes Dev. 24 (16),
1680–1694. http://dx.doi.org/10.1101/gad.1955310 (24/16/
1680 [pii]).
Kutler, D.I., Singh, B., Satagopan, J., Batish, S.D., Berwick, M.,
Giampietro, P.F., Hanenberg, H., Auerbach, A.D., 2003. A 20-
year perspective on the International Fanconi Anemia Registry
(IFAR). Blood 101 (4), 1249–1256. http://dx.doi.org/10.1182/
blood-2002-07-2170 (2002-07-2170 [pii]).
Liu, G.H., Suzuki, K., Li, M.,Qu, J.,Montserrat, N.,Tarantino, C.,Gu,
Y.,Yi, F.,Xu, X.,Zhang, W.,Ruiz, S.,Plongthongkum, N.,Zhang, K.,
Masuda, S., Nivet, E., Tsunekawa, Y., Soligalla, R.D., Goebl, A.,
Aizawa, E.,Kim, N.Y.,Kim, J.,Dubova, I.,Li, Y.,Ren, R.,Benner, C.,
Del Sol, A., Bueren, J., Trujillo, J.P., Surralles, J., Cappelli, E.,
Dufour, C.,Esteban, C.R., Izpisua Belmonte, J.C., 2014. Modelling
Fanconi anemia pathogenesis and therapeutics using integration-
free patient-derived iPSCs. Nat. Commun. 5, 4330. http://dx.doi.
org/10.1038/ncomms5330 (ncomms5330 [pii]).
Look, A.T., 1997. Oncogenic transcription factors in the human acute
leukemias. Science 278 (5340), 1059–1064.
Marion, R.M., Strati, K., Li, H., Murga, M., Blanco, R., Ortega, S.,
Fernandez-Capetillo, O., Serrano, M., Blasco, M.A., 2009. A p53-
mediated DNA damage response limits reprogramming to ensure
iPS cell genomic integrity. Nature 460 (7259), 1149–1153. http://
dx.doi.org/10.1038/nature08287 (nature08287 [pii]).
Milyavsky, M.,Gan, O.I.,Trottier, M.,Komosa, M.,Tabach, O.,Notta, F.,
Lechman, E.,Hermans, K.G.,Eppert, K.,Konovalova, Z.,Ornatsky,
O., Domany, E., Meyn, M.S., Dick, J.E., 2010. A distinctive DNA
damage response in human hematopoietic stem cells reveals an
apoptosis-independent role for p53 in self-renewal. Cell Stem Cell
7 (2), 186–197. http://dx.doi.org/10.1016/j.stem.2010.05.016
(S1934-5909(10)00226-2 [pii]).
Moldovan, G.L., D'Andrea, A.D., 2009. How the Fanconi anemia
pathway guards the genome. Annu. Rev. Genet. 43, 223–249.
http://dx.doi.org/10.1146/annurev-genet-102108-134222.
Muller, L.U., Milsom, M.D., Harris, C.E., Vyas, R., Brumme, K.M.,
Parmar, K.,Moreau, L.A.,Schambach, A.,Park, I.H.,London, W.B.,
Strait, K., Schlaeger, T., Devine, A.L., Grassman, E., D'Andrea, A.,
Daley, G.Q., Williams, D.A., 2012. Overcoming reprogramming
resistance of Fanconi anemia cells. Blood 119 (23), 5449–5457.
http://dx.doi.org/10.1182/blood-2012-02-408674 (blood-2012-
02-408674 [pii]).
Navarro, S., Moleiro, V.,Molina-Estevez, F.J., Lozano, M.L., Chinchon,
R.,Almarza, E.,Quintana-Bustamante, O.,Mostoslavsky, G.,Maetzig,
T., Galla, M., Heinz, N., Schiedlmeier, B., Torres, Y., Modlich, U.,
Samper, E.,Rio, P., Segovia, J.C.,Raya, A.,Guenechea, G., Izpisua-
Belmonte, J.C., Bueren, J.A., 2014. Generation of iPSCs from
genetically corrected Brca2 hypomorphic cells: implications in cell
reprogramming and stem cell therapy. Stem Cells 32 (2), 436–446.
http://dx.doi.org/10.1002/stem.1586.
Niedernhofer, L.J., 2008. DNA repair is crucial for maintaining
hematopoietic stem cell function. DNA Repair (Amst) 7 (3),
523–529. http://dx.doi.org/10.1016/j.dnarep.2007.11.012 (S1568-
7864(07)00413-2 [pii]).
Pace, P.,Mosedale, G.,Hodskinson, M.R.,Rosado, I.V.,Sivasubramaniam,
M.,Patel, K.J., 2010. Ku70 corrupts DNA repair in the absence of
the Fanconi anemia pathway. Science 329 (5988), 219–223.
http://dx.doi.org/10.1126/science.1192277 (science.1192277
[pii]).
Parmar, K., D'Andrea, A., Niedernhofer, L.J., 2009. Mouse models
of Fanconi anemia. Mutat. Res. 668 (1–2), 133–140. http://dx.
doi.org/10.1016/j.mrfmmm.2009.03.015 (S0027-5107(09)00117-1
[pii]).
Raya, A., Rodriguez-Piza, I., Guenechea, G., Vassena, R., Navarro, S.,
Barrero, M.J.,Consiglio, A.,Castella, M.,Rio, P.,Sleep, E.,Gonzalez,
F., Tiscornia, G., Garreta, E., Aasen, T., Veiga, A., Verma, I.M.,
250 K. Vanuytsel et al.Surralles, J., Bueren, J., Izpisua Belmonte, J.C., 2009. Disease-
corrected haematopoietic progenitors from Fanconi anaemia in-
duced pluripotent stem cells. Nature 460 (7251), 53–59. http://dx.
doi.org/10.1038/nature08129 (nature08129 [pii]).
Rocha, C.R., Lerner, L.K., Okamoto, O.K., Marchetto, M.C., Menck,
C.F., 2013. The role of DNA repair in the pluripotency and
differentiation of human stem cells. Mutat. Res. (1), 25–35.
http://dx.doi.org/10.1016/j.mrrev.2012.09.001 (S1383-5742(12)
00061-0 [pii]).
Sasaki, M.S., Tonomura, A., 1973. A high susceptibility of Fanconi's
anemia to chromosome breakage by DNA cross-linking agents.
Cancer Res. 33 (8), 1829–1836.
Schindler, D., Hoehn, H., 1988. Fanconi anemia mutation causes
cellular susceptibility to ambient oxygen. Am. J. Hum. Genet. 43
(4), 429–435.
Song, H.,Chung, S.K., Xu, Y., 2010. Modeling disease in human ESCs
using an efficient BAC-based homologous recombination system.
Cell Stem Cell 6 (1), 80–89. http://dx.doi.org/10.1016/j.stem.
2009.11.016 (S1934-5909(09)00623-7 [pii]).
Tulpule, A., Lensch, M.W., Miller, J.D., Austin, K., D'Andrea, A.,
Schlaeger, T.M., Shimamura, A., Daley, G.Q., 2010. Knockdown
of Fanconi anemia genes in human embryonic stem cells reveals
early developmental defects in the hematopoietic lineage. Blood
115 (17), 3453–3462. http://dx.doi.org/10.1182/blood-2009-
10-246694 (blood-2009-10-246694 [pii]).
Utikal, J., Polo, J.M.,Stadtfeld, M.,Maherali, N.,Kulalert, W.,Walsh,
R.M., Khalil, A., Rheinwald, J.G., Hochedlinger, K., 2009. Immor-
talization eliminates a roadblock during cellular reprogramminginto iPS cells. Nature 460 (7259), 1145–1148. http://dx.doi.org/
10.1038/nature08285 (nature08285 [pii]).
Waisfisz, Q., Morgan, N.V., Savino, M., de Winter, J.P., van Berkel,
C.G.,Hoatlin, M.E., Ianzano, L.,Gibson, R.A., Arwert, F., Savoia,
A., Mathew, C.G., Pronk, J.C., Joenje, H., 1999. Spontaneous
functional correction of homozygous Fanconi anaemia alleles
reveals novel mechanistic basis for reverse mosaicism. Nat.
Genet. 22 (4), 379–383. http://dx.doi.org/10.1038/11956.
Yao, Y., Nashun, B., Zhou, T.,Qin, L., Zhao, S., Xu, J., Esteban, M.A.,
Chen, X., 2012. Generation of CD34+ cells from CCR5-disrupted
human embryonic and induced pluripotent stem cells. Hum. Gene
Ther. 23 (2), 238–242. http://dx.doi.org/10.1089/hum.2011.126.
Yung, S.K., Tilgner, K., Ledran, M.H., Habibollah, S., Neganova, I.,
Singhapol, C., Saretzki, G., Stojkovic, M.,Armstrong, L.,Przyborski,
S.,Lako, M., 2013. Brief report: human pluripotent stem cell models
of Fanconi anemia deficiency reveal an important role for Fanconi
anemia proteins in cellular reprogramming and survival of hemato-
poietic progenitors. Stem Cells 31 (5), 1022–1029. http://dx.doi.
org/10.1002/stem.1308.
Zhang, S., Yajima, H., Huynh, H., Zheng, J., Callen, E., Chen, H.T.,
Wong, N.,Bunting, S.,Lin, Y.F.,Li, M.,Lee, K.J.,Story, M.,Gapud,
E.,Sleckman, B.P.,Nussenzweig, A.,Zhang, C.C.,Chen, D.J.,Chen,
B.P., 2011. Congenital bone marrow failure in DNA-PKcs mutant
mice associated with deficiencies in DNA repair. J. Cell Biol. 193
(2), 295–305. http://dx.doi.org/10.1083/jcb.201009074 (jcb.
201009074 [pii]).
